NF-κB Protects HIV-1-Infected Myeloid Cells from Apoptosis  by DeLuca, Carmela et al.
NF-kB Protects HIV-1-Infected Myeloid Cells from Apoptosis
Carmela DeLuca,*,† Hakju Kwon,*,† Nadine Pelletier,*,† Mark A. Wainberg,*,†,‡,§ and John Hiscott*,†,‡,§,1
*Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital; and ‡Department of Microbiology and Immunology
and †Department of Medicine, §McGill AIDS Centre, McGill University, Montreal, Quebec Canada H3T 1E2
Received November 7, 1997; returned to author for revision December 26, 1997; accepted February 11, 1998
HIV-1 infection of primary monocytic cells and myeloid cell lines results in sustained NF-kB activation. Recently, NF-kB
induction has been shown to play a role in protecting cells from programmed cell death. In the present study, we sought to
investigate whether constitutive NF-kB activity in chronically HIV-1-infected promonocytic U937 (U9-IIIB) and myeloblastic
PLB-985 (PLB-IIIB) cells affects apoptotic signaling. TNFa and cycloheximide caused infected cells to undergo apoptosis
more rapidly than parental U937 and PLB-985 cells. Inhibition of TNFa-induced NF-kB activation using the antioxidant
N-acetylcysteine (NAC) resulted in increased apoptosis in both U937 and U9-IIIB cells, while preactivation of NF-kB with the
non-apoptotic inducer IL-1b caused a relative decrease in apoptosis. Inhibition of constitutive NF-kB activity in U9-IIIB and
PLB-IIIB cells also induced apoptosis, suggesting that NF-kB protects cells from a persistent apoptotic signal. TNFa plus
NAC treatment resulted in a marked decrease in Bcl-2 protein levels in HIV-1-infected cells, coupled with an increase in Bax
protein compared to uninfected cells, suggesting that the difference in susceptibility to TNFa-induced apoptosis may relate
to the differences in relative levels of Bcl-2 and Bax. The protective role of NF-kB in blocking TNFa- and HIV-1-induced
apoptosis was supported by studies in Jurkat T cells engineered to express IkBa repressor mutants (TD-IkB) under the
control of a tetracycline-responsive promoter. Cells underwent apoptosis in response to TNFa only when NF-kB activation
was inhibited by TD-IkB expression. As was observed for the U9-IIIB cells, TNFa treatment also induced a marked decrease
in Bcl-2 protein levels in TD-IkB expressing cells. These experiments demonstrate that apoptotic signaling is perturbed in
HIV-1-infected U9-IIIB cells and indicate that NF-kB activation may play an additional protective role against HIV-1-induced
apoptosis in myeloid cells. © 1998 Academic Press
INTRODUCTION
HIV-1 infection is cytopathic for CD41 T cells but can
result in the chronic infection of CD41 myeloid cells. The
mechanism of myeloid cell protection from HIV-1 infec-
tion is unknown. As a consequence of the long-term
production of viral particles, chronically infected myeloid
cells have been suggested to act as reservoirs of virus,
propagating virus spread and disease progression
(Perno et al., 1997). HIV-1-induced apoptosis has been
proposed as one mechanism to explain the direct cyto-
pathic effects of virus infection, as well as apoptosis of
bystander lymphocytes (Maldarelli et al., 1995; Ameisen
et al., 1995; Herbein et al., 1998). CD41 myeloid cells may
be more resistant to the induction of apoptosis by HIV-1
infection.
NF-kB plays a central role in the HIV life cycle, facili-
tating replication at several levels. NF-kB is essential for
LTR-driven gene expression (reviewed in Roulston et al.,
1995) and has been reported to affect mRNA transport by
Rev (Wu et al., 1997). NF-kB interacts with HIV Tat, lead-
ing to synergistic activation of HIV gene transcription
(Chang et al., 1995; Demarchi et al., 1996). In addition, via
its ability to activate proinflammatory cytokines such as
TNFa (Lenardo and Baltimore, 1989), NF-kB activation
initiates an autostimulatory loop that increases HIV rep-
lication (Poli et al., 1990).
The NF-kB family of transcription factors is involved in
the transduction of immunological responses, cellular
differentiation, and cell growth regulation (reviewed in
Roulston et al., 1995; Verma et al., 1995; Baldwin, 1996).
NF-kB proteins are found in a latent state in the cyto-
plasm, complexed to inhibitory IkB proteins. Activation of
NF-kB results following exposure to a variety of inducing
agents including cytokines, bacterial and viral patho-
gens, chemotherapeutic compounds, and cell damaging
agents. Several DNA binding family members exist: p50
and p52 are synthesized as inactive precursors (p105
and p100, respectively) and are proteolytically cleaved to
produce the mature DNA binding proteins; p65 (RelA),
c-Rel and RelB contain, in addition to an N-terminal DNA
binding domain, C-terminal transactivation domains
(Baldwin, 1996). In unstimulated cells, NF-kB proteins are
sequestered in the cytoplasm, complexed with the IkB
inhibitor molecules which include IkBa, IkBb, IkBg, the
recently identified IkBe (Whiteside et al., 1997), and the
proto-oncogene bcl-3. IkB binds to NF-kB, masking nu-
clear localization sequences and preventing nuclear
translocation. Structurally, all IkBs (reviewed in Baldwin,
1996) contain between five and seven 33-amino-acid
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repeats termed the ankyrin motif, which is required for
interaction with NF-kB. Phosphorylation of serine resi-
dues 32 and 36 targets IkBa for ubiquitin-dependent
proteolytic degradation. A large multi-subunit kinase
complex that contains the IKK kinase activities required
for inducer mediated phosphorylation at Ser-32 and
Ser-36 was identified recently (Chen et al., 1996; Re´gnier
et al., 1997; DiDonato et al., 1997; Woronicz et al., 1997;
Mercurio et al., 1997); regulation of this kinase complex
remains to be elucidated.
Chronic HIV-1 infection of U937 promonocytic cells
(termed U9-IIIB) or the myelomonoblastic PLB-985
(termed PLB-IIIB) (Roulston et al., 1992) leads to consti-
tutive NF-kB expression (Bachelerie et al., 1991; Roulston
et al., 1992, 1993, 1995), increased proteasome-mediated
turnover of IkBa, and elevated expression of NF-kB1,
NF-kB2, and c-Rel proteins (McElhinny et al., 1995; De-
Luca et al., 1996). This modulation of intracellular NF-kB
levels may contribute to enhanced NF-kB-directed gene
expression and increased HIV-1 replication. Recently,
NF-kB activation was shown to protect cells from several
apoptotic stimuli, including TNFa, and inhibition of NF-kB
activity rendered resistant cells sensitive to TNFa-in-
duced apoptosis (Van Antwerp et al., 1996; Beg and
Baltimore, 1996; Wang et al., 1996; Wu et al., 1996). In
particular, RelA(p65) and c-Rel have been implicated as
subunits capable of conferring protection. RelA-/- mouse
embryonic fibroblasts are sensitive to TNFa toxicity but
become resistant when RelA is reexpressed by transfec-
tion (Beg and Baltimore, 1996), while microinjection of
GST-IkBa or anti-c-Rel affinity-purified antibody induced
apoptosis in mouse WEHI 231 cells (Wu et al., 1996).
NF-kB has also been implicated as a mediator of
apoptosis (Lin et al., 1995; Abbadie et al., 1993; Grimm et
al., 1996; Ivanov et al., 1997; Marianneau et al., 1997;
Lipton, 1997) since stimuli that lead to cell apoptosis
often lead to NF-kB activation (UV, TNFa, Fas, HIV infec-
tion, and various chemotherapeutic agents). Blocking
NF-kB induction can prevent apoptosis, although this
appears to be cell specific and in several situations,
NF-kB can be blocked without preventing apoptosis (Cai
et al., 1997; Hsu et al., 1996; Dbaido et al., 1997). The
mechanism by which NF-kB protects cells from apopto-
sis remains to be elucidated, although NF-kB activates
several protective genes implicated in anti-apoptotic ef-
fects including A20 (Jaattela et al., 1996; Tewari and Dixit,
1996), Bcl-2, c-Myc, p53 (Baichwal and Baeuerle, 1997),
and c-IAP2 (Chu et al., 1997). Bcl-2 is a mitochondrial
protein that protects against apoptosis in many cell sys-
tems; inactivation of Bcl-2 by degradation or phosphory-
lation permits mitochondrial proteases and cytochrome c
to enter the cytoplasm and execute apoptosis (Kluck et
al., 1997; Yang et al., 1997). The Bcl-2 family of proteins is
composed of pro-apoptotic and protective members (re-
viewed in Yang and Korsmeyer, 1996; Reed et al., 1996)
and the relative levels of these proteins influences
whether a cell lives or commits cell ‘‘suicide’’ by apopto-
sis. The HIV-1 Tat protein has been reported to modulate
Bcl-2 and Bax levels, suggesting that modulation of Bcl-2
proteins may be one mechanism used by HIV to induce
apoptosis in infected and bystander cells (Zauli et al.,
1995; Sastry et al., 1996; Zauli and Gibellini, 1996).
This study sought to determine whether HIV-1 infec-
tion of myeloid cells induced alterations in apoptotic
signaling pathways and whether NF-kB was involved.
Our results demonstrate that constitutive NF-kB activa-
tion is required to counteract a persistent apoptotic sig-
nal resulting from chronic HIV-1 infection and that NF-kB
is important in protecting cells from the cytotoxic effects
of TNFa in both the U937/U9-IIIB and PLB-985/PLB-IIIB
myeloid and Jurkat T cell lines. Thus, a previously unrec-
ognized role for constitutive NF-kB activation in HIV-1-
infected cells is to protect from virus-mediated apoptotic
cell death.
RESULTS
Increased apoptosis in HIV-1-infected U937 cells
Experiments presented in this paper derived from
three observations: (1) chronic HIV-1 infection of myeloid
cells results in constitutive NF-kB DNA binding activity
(Bachelerie et al., 1991; Roulston et al., 1992, 1993, 1995);
(2) NF-kB has a bipotential role in apoptotic signaling,
protective in some cells (Van Antwerp et al., 1996; Beg
and Baltimore, 1996; Wang et al., 1996) pro-apoptotic in
others (Lin et al., 1995; Jung et al., 1995; Abbadie et al.,
1993); and (3) HIV-1 infection is associated with virus-
induced apoptosis in susceptible cells (Maldarelli et al.,
1995; Ameisen et al., 1995; Herbein et al., 1998). We
therefore asked whether perturbation of NF-kB activity in
U937/U9-IIIB or PLB-985/PLB-IIIB cells resulted in al-
tered apoptotic signaling. U937 and U9-IIIB cells were
incubated in the presence of 10 ng/ml TNFa and 100
mg/ml cycloheximide (CHX) for 0 1, 2, 4 or 6 h and
analyzed for DNA fragmentation. Figure 1 illustrates that
FIG. 1. Chronically HIV-infected U9-IIIB cells undergo apoptosis in
response to TNFa/CHX more rapidly than uninfected U937 cells. Cells
were treated with the protein synthesis inhibitor cycloheximide (CHX,
100 mg/ml) and tumor necrosis factor a (TNFa, 10 ng/ml) for 0, 1, 2, 4,
or 6 h. 2 3 106 cells were lysed and analyzed for DNA fragmentation by
electrophoresis and visualized by ethidium bromide staining. Fragmen-
tation was visible after 1–2 h in U9-IIIB (lanes 7–8) cells but not until 4 h
in U937 cells (lane 4).
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U9-IIIB cells exhibited increased sensitivity to TNFa,
undergoing detectable DNA fragmentation as early as
1–2 h after TNFa treatment (Fig. 1, lanes 7 and 8) com-
pared to uninfected U937, which do not show visible
signs of apoptosis until 4 h (Fig. 1, lane 4). Increasing the
concentration of TNFa induced a more rapid induction of
apoptosis in both cell types (data not shown). Similar
results were obtained using promonocytic PLB-985 cells
and HIV-1-infected PLB-IIIB cells. These cells were
treated with TNFa (20 ng/ml) and CHX (50 mg/ml) for 0–5
h. Infected cells exhibited DNA laddering after 1 h, while
uninfected cells underwent fragmentation beginning at
2 h (data not shown).
Relationship between NF-kB levels and apoptosis
To assess the involvement of NF-kB in apoptotic sig-
naling, U937 and U9-IIIB cells were pretreated with the
antioxidant N-acetylcysteine (NAC 50 mM) for 1 h and
then with TNFa (20 ng/ml) and CHX (50 mg/ml) for 2 h;
NAC inhibited NF-kB activation by blocking IkB phos-
phorylation (Schreck et al., 1991; Staal et al., 1993; Lee et
al., 1997). The level of TNFa/CHX induced apoptosis was
increased in both U937 and U9-IIIB cells following NAC
pretreatment as quantified by the TUNEL assay (Figs. 2A
and 2B). TNFa/CHX induced approximately 30% apopto-
sis in U937 (Figs. 2A and 2C) and this value was in-
creased to 50% by NAC pretreatment. TNFa/CHX treat-
ment induced 35 to 70% apoptosis in U9-IIIB cells (Figs.
2B and 2D); NAC pretreatment resulted in a consistent
20–40% increase in apoptotic cells (Fig. 2B). Interestingly,
the combination of NAC/CHX induced significant apopto-
sis in U9-IIIB, whereas U937 cells were only marginally
affected. In addition, CHX alone caused a low level of
apoptosis in U9-IIIB cells (;10%), suggesting that a labile
FIG. 2. Inhibition of NF-kB increases — while preactivation of NF-kB decreases — TNFa/CHX-induced apoptosis. U937 (A) and U9-IIIB (B) cells
were pretreated with or without the antioxidant N-acetylcysteine (NAC, 50 mM) for 1 h or U937 (C) and U9-IIIB (D) cells were pretreated with or without
interleukin 1b (IL-1b, 5 ng/ml) for 5 h. Cells were subsequently treated with CHX (50 mg/ml) and/or TNFa (20 ng/ml) for 2 h. Apoptotic cells were
measured by TUNEL assay and the total cell numbers determined by Hoescht staining. Percentages of apoptotic cells were calculated with the results
plotted for an experiment carried out in triplicate.
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factor may be important for cell survival in HIV-1-infected
cells. Again, similar results were obtained using PLB-IIIB
cells (Table 1).
To determine if NF-kB preactivation would decrease
apoptosis, U937 and U9-IIIB cells were stimulated with
IL-1b (5 ng/ml), a noncytotoxic inducer of NF-kB, for 5 h
followed by a 2-h incubation with TNFa (20 ng/ml) and
CHX (50 mg/ml). In both cell types, addition of IL-1b
reduced both TNFa/CHX-induced apoptosis by approxi-
mately 40% and the low level of CHX-induced apoptosis
(Figs. 2C and 2D), again suggesting that a labile protein
induced by constitutive NF-kB, maintained cell survival.
Figure 3 illustrates cells positive for apoptosis by TUNEL
assay (right panels) within the total cell population (left
panels) induced by the treatments described in Fig. 2.
NF-kB DNA binding activity in TNFa-, IL-1b-, and NAC-
treated nuclear extracts was assessed by EMSA. Figure
4A illustrates that both TNFa and IL-1b induced NF-kB
DNA binding activity in U937 (Fig. 4A, lanes 4, 5, and 7)
and U9-IIIB cells (Fig. 4A, lanes 11, 12, and 14) and this
level of DNA binding was inhibited by NAC preincubation
(Fig. 4A, lanes 6 and 13, respectively). U9-IIIB cells ex-
hibited constitutive NF-kB DNA binding activity (Fig. 4A,
lane 8) which was abolished by NAC treatment (Fig. 4A,
lane 10); specificity of the complex was confirmed by
competition with a 125 molar excess of unlabeled com-
petitor DNA (Fig. 4A, lane 15). Figure 4B illustrates that
TNFa/CHX induced IkBa degradation in both U937 and
U9-IIIB cells (Fig. 4B, lanes 5, 7 and 12, 14, respectively)
and this degradation was inhibited by NAC pretreatment
(Fig. 4B, lanes 6 and 13), as recently described (Lee et al.,
1997). PLB-IIIB cells showed a similar pattern of IkBa
degradation in response to the conditions described
above (data not shown).
TNFa alone also induces DNA fragmentation in U937
and U9-IIIB cells, with the latter exhibiting signs of DNA
fragmentation earlier than noninfected cells. U937 and
U9-IIIB cells were incubated with TNFa (20 ng/ml) and/or
NAC (30 mM) for 0 to 48 h and in all cases NAC was
added to cells 1 h prior to TNFa addition. U937 cells did
not undergo apoptosis when incubated with NAC (Fig.
5A, lane 2) but underwent DNA fragmentation when
incubated with TNFa (Fig. 5A, lane 3) or TNFa and NAC
(Fig. 5A, lane 4). In contrast, U9-IIIB cells were sensitive
to all three treatments, undergoing DNA fragmentation
by 8 h after NAC (Fig. 5A, lane 6), TNFa (Fig. 5A, lane 7)
or TNFa plus NAC (Fig. 5A, lane 8) addition. Electro-
phoretic mobility shift analyses (EMSA) of nuclear ex-
tracts from TNFa- and/or NAC-treated cells confirmed
that NAC inhibited both TNFa-induced NF-kB binding
and constitutive NF-kB in HIV-1-infected cells (Fig. 5B).
NF-kB binding was detected in TNFa-induced extracts
from U937 and U9-IIIB cells (Fig. 5B, lanes 3 and 7,
respectively) but was reduced by NAC preincubation
(Fig. 5B, lanes 4 and 8). In addition, constitutive NF-kB in
U9-IIIB cells (Fig. 5B, lane 5) was blocked by NAC (Fig.
5B, lane 6).
Bcl-2/Bax expression in HIV-infected cells
These results suggest that NF-kB may regulate genes
important in protecting cells from apoptosis. One candi-
date gene is bcl-2, an inhibitor of apoptosis that is known
to be NF-kB regulated (Baichwal and Baeurele, 1997). To
analyze Bcl-2 expression, U937 and U9-IIIB cells were
treated with NAC (30 mM), TNFa (20 ng/ml), or TNFa/
NAC for 0, 8, 16, 24, or 48 h and whole cell extracts (50
mg) were examined for Bcl-2 levels. NAC had little effect
on Bcl-2 levels in U937 cells but resulted in a decrease
in Bcl-2 protein level in U9-IIIB cells (data not shown).
TNFa/NAC treatment caused a significant decrease in
Bcl-2 protein with time in U9-IIIB cells (Fig. 6A, lanes
6–10) but only a slight decrease in U937 cells (Fig. 6A,
lanes 1–5). Bcl-2 protein levels relative to actin levels are
plotted as a function of time for TNFa/NAC-treated cells.
Bcl-2 protein levels were approximately equal in U937
and HIV-1-infected U937 cells and therefore could not
account for the difference in sensitivity of U937 and
U9-IIIB cells to TNFa-induced apoptosis. Previous stud-
ies demonstrated that HIV-1 Tat expression resulted in
increased Bax expression, a pro-apoptotic member of
the Bcl family (Sastry et al., 1996). To determine whether
differential expression of Bax contributed to the differ-
ences in sensitivity to apoptosis in U9-IIIB cells, extracts
were prepared from cells treated with NAC, TNFa, or
TNFa/NAC for 24 h. U9-IIIB cells expressed approxi-
mately two- to threefold higher levels of Bax compared to
U937 cells (Fig. 6B, lanes 1 and 5). NAC treatment did not
affect Bax in U937 cells or U9-IIIB cells (Fig. 6B, lanes 2
and 6), while TNFa treatment increased Bax levels ap-
proximately two-fold in U937 and U9-IIIB (Fig. 6B, lanes 3
and 7, respectively). NAC only partially inhibited TNFa-
induced increase in Bax protein in U937 and U9-IIIB cells
(Fig. 6B, lanes 4 and 8).
TABLE 1
Effect of NF-kB Activation on TNFa/CHX-Induced Apoptosis
in PLB-IIIB Cells
Condition Percentage of Apoptosis
Untreated 1.3
Cycloheximide 11.9 6 0.54
NAC 1 cycloheximide 33.5 6 2.2
IL-1b 1 cycloheximide 6.9 6 0.57
TNFa 1 cycloheximide 39.8 6 5.2
NAC 1 TNFa 1 cycloheximide 57.5 6 1.7
IL-1b 1 TNFa 1 cycloheximide 27.9 6 3.4
Note. PLB-IIIB cells were pretreated with IL-1b (10 ng/ml) for 5 h or
NAC (50 mM) for 1 h and were subsequently incubated with TNFa (20
ng/ml)/CHX (50 mg/ml) for 2 h. The number of apoptotic cells was
quantified by TUNEL assay. Values are the result of an experiment
performed in triplicate.
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FIG. 3. TUNEL analysis of U937 cells pretreated with NAC or IL-1b followed by TNFa/CHX treatment. U937 cells were treated with NF-kB inducers
or inhibitors, fixed, analyzed for TUNEL positivity and photographed (magnification 2003). (A) Cells were pretreated with NAC (50 mM) for 1 h followed
by CHX (50 mg/ml) for 2 h. (B) Cells were treated with TNFa (20 ng/ml) and CHX (50 mg/ml) for 2 h. (C) Cells were pretreated with NAC (50 mM) for
1 h and incubated with TNFa (20 ng/ml) and CHX (50 mg/ml) for 2 h. (D) Cells were pretreated with interleukin-1b (IL-1b, 5 ng/ml) for 5 h and stimulated
with TNFa (20 ng/ml) and CHX (50 mg/ml) for 2 h. Total cells (on the left) were stained with Hoechst 33342, while apoptotic cells (on the right) were
detected using the TUNEL assay (Boehringer Mannheim), as described under Materials and Methods.
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Induction of apoptosis in T cells expressing IkBa
repressor mutants
The protective role of NF-kB in preventing TNFa-in-
duced apoptosis was verified in Jurkat T cells inducibly
expressing nondegrading transdominant forms of IkBa
(TD-IkB) under the control of a tetracycline-responsive
promoter (Kwon et al., 1998). In this system doxycycline
(Dox) addition induces high levels of TD-IkB which ef-
fectively block TNFa-induced NF-kB activation (Kwon et
al., 1997). Control Jurkat cells (rtTA-Neo) and Jurkat cells
expressing the IkB repressors (rtTA-IkB-2N and rtTA-IkB-
2ND4, mutated at S32/36A) were incubated with or with-
out Dox (1 mg/ml) for 16 h followed by TNFa (20 ng/ml)
treatment for 0–24 h. As shown in Fig. 7, TNFa did not
induce apoptosis in control rtTA-Neo cells in either the
absence or the presence of Dox (Fig. 7A, lanes 1–5 and
6–10). Similarly, no DNA fragmentation was observed in
the absence of Dox in the rtTA-IkB-2N and rtTA-IkB-2ND4
cells (Figs. 7B and 7C, lanes 1–5). In contrast, rtTA-
IkB-2N and rtTA-IkB-2ND4 cells displayed DNA fragmen-
tation after Dox induction (expression of the IkB repres-
sors) and TNFa addition (Figs. 7B and 7C, lanes 6–10),
demonstrating an increased sensitivity to apoptosis in
cells blocked for NF-kB-dependent activity.
Dox induction of TD-IkB repressors was verified by
immunoblot analysis (Fig. 8A) and the subsequent inhi-
bition of NF-kB DNA binding activity was observed by
EMSA (Fig. 8B). Addition of Dox to rtTA-2N and rtTA-2ND4
resulted in increased TD-IkB levels (Fig. 8A, lanes 5, 6, 8,
and 9); interestingly, as previously described, activation
of the 2ND4 mutant resulted in the inhibition of endoge-
nous IkBa, as distinguished from endogenous IkBa us-
ing the MAD 10B antibody (Arenzana-Seisdedos et al.,
1995) (Fig. 8A, lanes 7–9). Furthermore, TNFa stimulation
did not affect TD-IkB (Fig. 8B, lanes 6 and 9). Nuclear
extracts from these cells confirmed that NF-kB could be
activated in all three cell lines in the absence of Dox (Fig.
8B, lanes 2, 6, and 10). Dox treatment for 24 h led to the
complete inhibition of TNFa induced binding activity in
cells expressing TD-IkB (Fig. 8B, lanes 8 and 12) but not
in control cells (Fig. 8B, lane 4). rtTA2N (Fig. 8C, lanes
FIG. 4. Analysis of NF-kB DNA binding activity and IkBa protein
levels. (A) Nuclear extracts from samples treated as in Fig. 2 were
analyzed for NF-kB activity using a 32P-labeled probe containing two
NF-kB sites from the IFN-b promoter. U9-IIIB cells exhibit constitutive
NF-kB binding activity (lane 8) that is increased by TNFa and IL-1b
(lanes 11, 12, and 14). U937 cells exhibit binding activity upon TNFa
and/or IL-1b stimulation (lanes 4, 5, and 7). NAC pretreatment inhibited
both the constitutive binding activity in U9-IIIB cells (lane 10) as well as
TNFa-induced NF-kB binding (lanes 6 and 13). (B) Whole cell extracts
were made from cells treated as described in Fig. 2 and protein (30 mg)
was separated by SDS–PAGE and blotted for IkBa protein. IkBa is
degraded by TNFa in both U937 (lanes 5 and 7) and U9-IIIB cells (lanes
12 and 14) and this degradation is blocked by pretreatment with NAC
(lanes 6 and 13, respectively). Equal amounts of protein were confirmed
by actin staining (data not shown).
FIG. 5. NAC treatment induces DNA fragmentation in U9-IIIB cells
but not in U937 cells. (A) U937 and U9-IIIB cells were treated with NAC
(30 mM) or TNFa (20 ng/ml) or both for 24 h. Samples were collected
and analyzed for DNA fragmentation. U937 cells undergo apoptosis in
response to TNFa (lane 3) or TNFa plus NAC (lane 4). U9-IIIB cells are
also sensitive to TNFa (lane 7) or TNFa plus NAC treatment (lane 8) but
in addition exhibit DNA fragmentation when treated with only NAC
(lane 6). (B) DNA fragmentation correlates with NF-kB binding activity.
Nuclear extracts were made from U937 and U9-IIIB cells treated as
above. NAC inhibits constitutive NF-kB activity in U9-IIIB cells (lane 6)
as well as TNFa induced binding in both cell lines (lanes 4 and 8).
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7–12) and rtTA2ND4 (Fig. 8C, lanes 13–18) cells induced
to express the TD-IkB repressors also downregulated
Bcl-2 protein levels upon prolonged TNFa treatment,
indicating that bcl-2 expression is controlled by NF-kB
induction. Bcl-2 levels in control cells were not affected
(Fig. 8C, lanes 1–6) and equal protein was confirmed by
actin staining (data not shown). rtTA-Jurkat cells were
subsequently treated with combinations of NAC, CHX,
and TNFa in the absence of TD-IkB induction to deter-
mine if inhibition of NF-kB by NAC rather than TD-IkB
expression produced similar results. As shown in Table
2, TNFa/CHX treatment induced apoptosis which was
further augmented by NAC pretreatment, as was de-
scribed above for myeloid cells.
DISCUSSION
Macrophages and cells of the myeloid lineage are
permissive for HIV-1 infection but infection is generally
not cytolytic, leading to the concept that cells of the
myeloid lineage may serve as viral reservoirs capable
of transmitting virus to CD41 T cells. The inherent
phagocytic properties of monocytes and macro-
phages, coupled with their ability to migrate through-
out the body, likely contribute to the extensive dissem-
ination of virus observed in HIV-1 infection (reviewed
in Perno et al., 1997).
NF-kB has been implicated in the regulation of stimu-
lus-induced apoptosis, inducing cell death in some cir-
cumstances (Baeuerle and Baltimore, 1996; Lin et al.,
1995; Jung et al., 1995; Abbadie et al., 1993) and protect-
ing in others (Van Antwerp et al., 1996; Beg and Balti-
more, 1996; Wang et al., 1996). The results of the present
study indicate that TNFa induces apoptosis in U937 and
U9-IIIB cells and the extent of cytotoxicity is inversely
correlated with the level of NF-kB activation. Inhibition of
NF-kB activation using the anti-oxidant NAC increased
apoptosis in both infected and noninfected cells. Con-
versely, deliberate activation of NF-kB by the noncyto-
FIG. 6. Bcl-2 and Bax protein levels in U937 and U9-IIIB cells. U937 and U9-IIIB cells were treated with TNFa (20 ng/ml) and NAC (30 mM) for 0,
8, 16, 24, or 48 h. Whole cell extracts were electrophoresed and blotted for Bcl-2 and b-actin protein levels. The ratio of Bcl-2 to b-actin was calculated
and plotted on a semi-log scale. (A) Bcl-2 levels dramatically decrease in NAC/TNFa-treated U9-IIIB cells while showing only a modest decrease in
U937. (B) The 24-h time points were analyzed for Bax levels by Western blot analysis. U937 cells (left panel) express barely detectable levels of Bax
protein, which increases upon TNFa induction (lane 3). U9-IIIB cells (right panel) express a higher level of Bax protein (lane 5) that is further
augmented by TNFa treatment (lane 7).
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toxic inducer IL-1b partially rescued cells from TNFa/
CHX-induced apoptosis. In T cells, NF-kB antagonized
TNFa-induced apoptosis and conversely its inhibition
exacerbated TNFa cytotoxicity.
Interestingly, NAC incubation alone or CHX/NAC-in-
duced HIV-1-infected cells to undergo apoptosis. HIV-1-
infected monocytic cells may receive a persistent apop-
totic signal that is countered by the maintenance of a
redox-sensitive, NF-kB-induced, anti-apoptotic protein.
Although HIV-1-infected cells constitutively express NF-
kB, they are still more sensitive to TNFa-mediated cyto-
toxicity. This may suggest that HIV-1 infection propels an
apoptotic pathway in myeloid lineage cells that is coun-
tered by NF-kB activation. Cells are therefore more sen-
sitive to further cytotoxic insults since an apoptotic path-
way is ready to be executed. The effect of NAC on
chronically infected U9-IIIB cells may be similar to its
effect on TNFa-induced apoptosis. Productive HIV-1 in-
FIG. 8. TD-IkBa is resistant to TNFa-induced degradation and leads
to decreased Bcl-2 expression in TNFa-treated cells. Jurkat rtTA-Neo,
rtTA-2N, and rtTA-2ND4 cells were incubated with or without Dox (1
mg/ml) for 24 h to induce expression of the IkBa mutants. Cells were
subsequently treated with TNFa (20 ng/ml) for 24 h. (A) Western blot
analysis of whole cell extracts was performed using an N-terminal IkBa
mAb which identifies both endogenous IkBa and the C-terminal trun-
cated 2ND4 (lower band). IkBa levels were unchanged by Dox addition
to control rtTA-Neo cells (compare lanes 1 and 2) or by TNFa addition
for 24 h (lane 3). Dox induction of rtTA-2N and rtTA-2ND4 cells led to
increased IkBa expression (lanes 5 and 8) which was not degraded
upon TNFa stimulation (lanes 6 and 9). (B) Electrophoretic mobility shift
assay (EMSA) analysis illustrated that NF-kB activation by TNFa was
blocked in Dox-treated cells expressing the TD-IkBa (lanes 8 and 12)
but not in control rtTA-Neo cells (lane 4). (C) Western blot analysis of
Bcl-2 levels also revealed that Dox-treated Jurkat rtTA-2N (lanes 7–12)
and rtTA-2ND4 (lanes 13–18) but not rtTA-Neo (lanes 1–6) cells de-
creased Bcl-2 levels with increased TNFa incubation.
FIG. 7. TD-IkB expression induces sensitivity to TNFa-signaled ap-
optosis. Jurkat T cells inducibly expressing IkBa mutated in two critical
serine residues, abolishing inducer-mediated degradation, were
treated with TNFa (20 ng/ml) for 0, 4, 8, 16, or 24 h. IkBa was induced
prior to TNFa treatment with doxycycline (Dox 1 mg/ml) for 16 h. TNFa
treatment does not induce DNA fragmentation in control rtTA-Neo (A)
cells but does in rtTA-2N (B) and rtTA-2ND4 (C) which express trans-
dominant IkBa (compare lanes 1–5 and 6–10).
TABLE 2
NAC Inhibition of TNFa-Induced NF-kB Activation Augments
Apoptosis in Jurkat Cell Lines
Condition rtTA-Neo rtTA-2ND4
Control 0.52 8.2
Cycloheximide 14.1 6 0.54 17.5 6 1.8
NAC 1 cycloheximide 14.4 6 1.3 15.2 6 1.2
TNFa 1 cycloheximide 22.0 6 1.2 30.6 6 2.1
NAC 1 TNFa 1 cycloheximide 54.5 6 8.7 45.0 6 4.5
Note. Jurkat rtTA-Neo, rtTA-2N, and rtTA-2ND4 cells were pretreated
with NAC (30 mM) for 1 h and stimulated with TNFa(30 ng/ml)/CHX (50
mg/ml) for 2 h. Tunel assay was used to quantitate the number of
apoptotic cells. Values are the average percentage of apoptosis of two
experiments.
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fection leads to increased TNFa expression, which may
stimulate cells by an autocrine regulatory mechanism.
Constitutive expression of TNFa mRNA is present in
U9-IIIB but not U937 cells and can be induced to higher
levels in HIV-1-infected cells (Lacoste et al., 1990). Also,
U9-IIIB cells strongly upregulate IL-1b gene transcription
and protein production in response to PMA stimulation,
while U937 cells do not express detectable IL-1b mRNA
(D’Addario et al., 1992). Increased TNFa and/or IL-1b
levels would activate NF-kB and protect cells from HIV-
1-induced apoptosis. Alternatively, HIV-1 infection may
affect another apoptotic pathway that is sensitive to
NF-kB inhibition.
NF-kB activation potently stimulates HIV-1 replication
by inducing LTR-driven gene expression (reviewed in
Roulston et al., 1995) and is responsible for the robust
viral replication seen upon TNFa stimulation. NF-kB is
also responsible for the activation of numerous cellular
genes, including immunoregulatory molecules and cyto-
kines. Activation of NF-kB by various stimuli including
TNFa, which transduce their activation signal through
radical oxygen intermediates (ROI), can be inhibited by
pretreating cells with the antioxidant NAC. NAC is
thought to inhibit signaling directly through its capacity
as a ROI scavenger as well as through its ability to
replenish cellular glutathione (GSH) levels (Staal et al.,
1993). Replenishing GSH strongly suppressed HIV-1 rep-
lication in human macrophages (Garaci et al., 1997), as
did NAC addition in latently infected cell lines (Roederer
et al., 1991) and PBMC (Roederer et al., 1990). Others
have found that NAC did not affect HIV-1 replication in
chronically infected promonocytic U937 cells (Aillet et al.,
1994) or actually stimulated HIV-1 virus replication in
monocyte-derived macrophages (Nottet et al., 1997).
Murine macrophages and fibroblasts deficient in the
prototypical transactivating NF-kB subunit RelA are
highly sensitive to TNFa-induced apoptosis (Beg and
Baltimore, 1996) and reintroduction of RelA repressed
the toxic effects of TNFa. Membrane interaction with
antibodies against IgM in WEHI 231 B cells also induces
apoptosis that is exacerbated by the inhibition of NF-kB
(Wu et al., 1996). Ectopic expression of c-Rel rescued
these cells from anti-IgM-induced apoptosis, while mi-
croinjection with a GST-IkBa fusion protein or anti-c-Rel
antibody induced cell death. Interestingly, we previously
reported dramatic increases in c-Rel protein levels in
both U937 and U9-IIIB cells upon TNFa stimulation (De-
Luca et al., 1996). It will be interesting to determine if
c-Rel is involved in protecting these cells from apoptosis.
The anti-apoptotic effects of NF-kB are supported by
experiments in Jurkat cells which are engineered to
inducibly express transdominant IkBa repressors (TD-
IkB) (Kwon et al., 1998). Normally resistant to TNFa
toxicity, Jurkat cells treated with TNFa underwent rapid
apoptosis when NF-kB induction was abolished by the
induction of TD-IkB. Similar results were obtained by
Verma and colleagues (Van Antwerp et al., 1996), who
examined TNFa-induced apoptosis in cells constitutively
overexpressing a transdominant IkBa mutant harboring
the Ser-32/36-Ala modification in the signal response
domain. Both the sensitivity and the kinetics of TNFa-
induced apoptosis were enhanced in the cell lines tested
(Van Antwerp et al., 1996). Together with the previous
studies, our results indicate that S32/36A mutations are
sufficient to confer sensitivity to TNFa-induced apopto-
sis. Additionally, Jurkat cells pretreated with NAC, in the
absence of TD-IkB expression, exhibited heightened
sensitivity to TNFa/CHX-induced apoptosis. These re-
sults suggest that the effect of NAC on TNFa-induced
apoptosis in HIV-1-infected and noninfected U937 cells
is due to inhibition of NF-kB activation.
Various NF-kB-regulated anti-apoptotic gene products
are known to protect cells from programmed cell death,
including the zinc finger protein A20 (Jaattela et al., 1996;
Tewari and Dixit, 1996) and members of the Bcl-2 family
(reviewed in Yang and Korsmeyer, 1996; Reed et al.,
1996). Expression of A20 in Jurkat cells expressing a
transdominant IkBa mutant did not restore protection
from TNFa-induced apoptosis (Van Antwerp et al., 1996),
suggesting that it is either not the target of NF-kB trans-
activation or that it acts in cooperation with other anti-
apoptotic genes.
Bcl-2 expression counters apoptotic signaling by a vast
array of inducers in many cell models (reviewed in Yang
and Korsmeyer, 1996). Several Bcl-2 proteins have been
identified in mammals including Bcl-xL, Bcl-w, and Mcl-1,
which inhibit apoptosis, and Bax, Bik, Bak, Bad, and Bcl-xs,
which activate apoptosis. Cell fate is determined by the
relative ratio of anti- and pro-apoptotic members. De-
creased Bcl-2 levels have been reported to account for the
induction of apoptosis by HIV-1 infection in some cell sys-
tems (Strack et al., 1996; DeRossi et al., 1994). Although
Bcl-2 levels were comparable in infected and noninfected
cells, the level of Bax was elevated in HIV-1-infected U937
cells, suggesting that increased Bax expression may con-
tribute to the rapid induction of apoptosis observed in
HIV-1-infected cells. Bcl-2 expression decreased in TNFa-
treated Jurkat cells which were deficient in NF-kB induction
because of TD-IkB expression but not in cells in which
NF-kB could be activated. Bcl-2 levels were also modulated
by TNFa and NAC treatments in U937 and U9-IIIB, although
the decreases were not dramatic. This was particularly true
in noninfected cells, suggesting that other NF-kB-regulated
proteins may be important in protecting these cells from
TNFa-induced apoptosis. During the review of this work,
c-IAP2 was identified as an NF-kB-regulated gene involved
in the suppression of TNFa-induced cell death (Chu et al.,
1997). It will be interesting to determine if c-IAP2 expression
is dysregulated in HIV-1-infected myeloid cells. Macro-
phages and cells of the monocyte lineage produce TNFa in
response to viral challenge and are important perpetrators
of viral spread in HIV infection. Understanding the basis of
monocyte resistance to HIV-1-induced cytopathic effects
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may be crucial to limiting viral dissemination and battling
the devastation of AIDS.
MATERIALS AND METHODS
Cell culture
Promonocytic U937 and HIV-1 infected U9-IIIB cells, as
well as myelomonoblastic PLB-985 and HIV-1-infected
PLB-IIIB cells (infected with HIV strain IIIB) were main-
tained in RPMI 1640 (GIBCO, Life Technologies Inc.,
Grand Island, NY) supplemented with 5% Fetal Clone
(Hyclone, Logan, Utah), 2 mM L-glutamine, and 20 mg/ml
gentamicin (Schering Canada, Pointe Claire, Quebec).
Jurkat T cells stably expressing Dox-inducible transdomi-
nant mutants of IkBa (rtTA Jurkat 2N, containing an IkBa
mutated in at S32A/S36A; rtTA Jurkat 2ND4, containing
an IkBa mutated at S32A/S36A and 22-aa C-terminal
truncation) or the empty Neo vector (rtTA-Neo-Jurkat)
were previously described (Kwon et al., 1998). Cells were
grown in RPMI 1640 supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, and 20 mg/ml gentamicin. The
transgenes were induced by the addition of Dox (1 mg/
ml) to the culture medium for a minimum of 16 h. Cells
were seeded at a density of 0.5 3 106 cells/ml for all
experiments and treated with various inducers as indi-
cated in the figure legends: 10–30 ng/ml of recombinant
human TNFa (0.1% BSA in PBS, R&D Systems), 5–10
ng/ml IL-1b (0.1% BSA in PBS, R&D Systems), 30–50 mM
N-acetylcysteine (PBS, pH 7.5, Boehringer Mannheim),
and 50–100 mg/ml cycloheximide (Sigma).
Western blot analysis
Whole cell extracts were prepared by resuspension in
NP-40 lysis buffer (10 mM Tris–HCl, pH 8.0, 60 mM KCl,
1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM PMSF, and
0.01 mg/ml each of leupeptin, pepstatin, and aprotinin).
After incubation on ice for 10 min, cellular debris was
removed by a 10-min centrifugation at 4°C. Cell extracts
(20–100 mg) were resolved by SDS–PAGE and then
transferred to a nitrocellulose membrane. Membranes
were blocked for a minimum of 2 h in 5% skim milk and
incubated overnight in 5% milk containing anti-peptide
monoclonal or polyclonal antisera (dilutions ranged from
1:250 to 1:1000). Monoclonal IkBa antiserum MAD-10B
was a kind gift from Ron Hay (Jaffray et al., 1995). Anti-
serum AR20, which recognizes the N-terminus of IkBa
(aa 2–16), was prepared as described previously (Pepin
et al., 1994). Monoclonal anti-Bcl-2 and polyclonal anti-
Bax were purchased from Santa Cruz Inc. and monoclo-
nal anti b-actin was purchased from Boehringer Mann-
heim. The membranes were rinsed four times in PBS and
incubated with a secondary antibody, FITC-conjugated
goat anti-rabbit, or rabbit anti-mouse (1:1000, Amersham)
for 1 h at room temperature and then rinsed again four
times in PBS. The ECL–Western blotting detection sys-
tem (NEN Life Sciences) was used according to manu-
facturer’s instructions to visualize the specific signals.
Autoradiograms were scanned by laser scanner and
quantified using NIH Image 1.60 software. Bcl-2:actin
ratios are presented relative to levels in unstimulated
cells. Values were plotted on a semi-log scale and the
best fit curves were determined. The experiments were
repeated a minimum of three times and representative
autoradiograms are shown.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from untreated cells
or cells treated for varying times with one or a combina-
tion of the following inducers: TNFa (20 ng/ml), N-ace-
tylcysteine (50 mM), IL-1b (5 ng/ml), and cycloheximide
(50 mg/ml). Briefly, cells were washed in Buffer A (10 mM
HEPES, pH 7.9; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM
dithiothreitol (DTT); and 0.5 mM phenylmethylsulfonyl
flouride (PMSF)) and were resuspended in Buffer A con-
taining 0.1% NP-40. Cells were then chilled on ice for 10
min before being centrifuged at 10,000 g. Pellets were
then resuspended in Buffer B (20 mM HEPES, pH 7.9;
25% glycerol; 0.42 M NaCl2; 1.5 mM MgCl2; 0.2 mM EDTA;
0.5 mM DTT; 0.5 mM PMSF; 5 mg/ml leupeptin; 5 mg/ml
pepstatin; 0.5 mM spermidine; 0.15 mM spermine; and 5
mg/ml aprotinin). Samples were incubated on ice for 15
min before being centrifuged at 10,000 g. Nuclear extract
supernatants were diluted with Buffer C (20 mM HEPES,
pH 7.9; 20% glycerol; 0.2 mM EDTA; 50 mM KCl; 0.5 mM
DTT; and 0.5 mM PMSF). Nuclear extracts were sub-
jected to EMSA using a 32P-labeled probe corresponding
to the PRDII region of the IFN-b promoter (59-GGAAAT-
TCCGGGAAATTCC-39) as described (Arai et al., 1990).
The resulting protein–DNA complexes were resolved by
a 5% Tris–glycine gel and exposed to X-ray film. To
demonstrate the specificity of protein–DNA complex for-
mation, a 125-fold molar excess of unlabeled oligonucle-
otide was added to the nuclear extract before adding the
labeled probe.
DNA fragmentation
Following treatments, ;2 3 106 cells were pelleted,
washed with phosphate-buffered saline (PBS), resus-
pended in 250 ml of lysis buffer (20 mM Tris–HCl, pH 7.5;
10 mM borate; 0.25% NP-40; 0.1 mg/ml RNase), and
incubated for 1 h at 37°C. Proteinase K was added to a
final concentration of 1 mg/ml and extracts were incu-
bated for an additional hour. Samples were separated on
a 1.8% agarose gel containing 0.5 mg/ml ethidium bro-
mide and visualized by UV illumination.
TUNEL analysis
Apoptosis was quantified using an in situ cell death
detection kit (Boehringer Mannheim). Approximately 1 3
106 cells were centrifuged, washed once with PBS, and
resuspended in 20 ml of PBS. Cells were plated on a
multichamber slide, air dried, and fixed with 4% parafor-
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maldehyde for 30 min at room temperature. Slides were
rinsed twice with PBS and incubated for 2 min at 4°C in
permeabilization solution (0.1% Triton; 0.1% sodium ci-
trate), rinsed with PBS, and incubated with fluorescein-
labeled TUNEL reaction mixture for 1 h at 37°C in a
humid, darkened chamber. Slides were again rinsed with
PBS, incubated with the nuclear dye Hoescht 33342 (0.4
ng/ml) to stain all nuclei, washed with PBS, and embed-
ded in mounting solution (10 mM Tris–HCL, pH 8.8; 0.1 M
propylgallate in glycerol). Samples were analyzed by
fluorescence microscopy and the percentage of apopto-
tic cells was determined by counting a minimum of 350
nuclei (blue filter) and the corresponding TUNEL-positive
cells (green filter).
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